Classement en actions
#27062
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Prix de l'action
$2.04
Dernière synchronisation: 2025-12-09
Capitalisation boursière
$35.38M
Changement (1 jour)
0.00%
Échange Mural Oncology plc (MURA)
Le prix MURA avec la capitalisation boursière de B
Capitalisation boursière de Mural Oncology plc(MURA)
Capitalisation boursière: $35.38M
En August 2026, Mural Oncology plc a une capitalisation boursière de $35.38M. Cela fait de Mural Oncology plc la 27062nd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Mural Oncology plc du 2023 au 2026
MURA par rapport au top 5 des plus populaires stocks
| Prix pour MURA |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.301T
|
+14,980,430.71%
|
|
|
|
|
$4.634T
|
+13,095,454.05%
|
|
|
|
|
$4.143T
|
+11,708,180.82%
|
|
|
|
|
$3.589T
|
+10,143,655.51%
|
|
|
|
|
$2.857T
|
+8,073,786.56%
|
